Treatment of hepatitis C in children with direct-acting antiviral drugs

Krestine Rosager Hansen, Jesper Kjærgaard, Helene Kvistgaard, Dorthe Grosen, Mette Holm, Jan Gerstoft, Sannie Nordly, Thora Wesenberg Helt, Vibeke Brix Christensen*

*Corresponding author af dette arbejde

Abstract

The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

Bidragets oversatte titelTreatment of hepatitis C in children with direct-acting antiviral drugs
OriginalsprogDansk
ArtikelnummerV08230522
TidsskriftUgeskrift for Laeger
Vol/bind186
Udgave nummer1
ISSN0041-5782
DOI
StatusUdgivet - 1 jan. 2024

Emneord

  • Antiviral Agents/adverse effects
  • Child
  • Hepacivirus
  • Hepatitis C
  • Hepatitis C, Chronic/drug therapy
  • Humans
  • Liver Cirrhosis/complications

Fingeraftryk

Dyk ned i forskningsemnerne om 'Treatment of hepatitis C in children with direct-acting antiviral drugs'. Sammen danner de et unikt fingeraftryk.

Citationsformater